Stockscreener 앱 받기
225.60
2.21%
-5.10
시간 외 거래:
225.60
전일 마감가:
$230.70
열려 있는:
$230.13
하루 거래량:
417.35K
Relative Volume:
0.58
시가총액:
$14.84B
수익:
$1.01B
순이익/손실:
$581.90M
주가수익비율:
25.42
EPS:
8.8733
순현금흐름:
$50.57M
1주 성능:
-4.70%
1개월 성능:
-10.83%
6개월 성능:
+2.13%
1년 성능:
+18.90%
1일 변동 폭
$224.26
$230.43
1주일 범위
$220.23
$241.50
52주 변동 폭
$186.05
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
225.60 | 14.84B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S 주식(ASND)의 최신 뉴스
Enterprise value of Ascendis Pharma A/S – FWB:A710 - TradingView
Total operating expenses of Ascendis Pharma A/S – FWB:A710 - TradingView
Ascendis Pharma Falls as Investors Reassess Novo Rights Reversion and Pipeline Execution Risk - Moomoo
Ascendis Pharma (NASDAQ: ASND) Severs Novo Nordisk Tie To Take Full Control Of TransCon Metabolic Pipeline - foreignpolicyjournal.com
Ascendis Pharma A/S (ASND) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273 - Moomoo
Ascendis Pharma A/S (ASND) Stock Analysis: Exploring a Potential 31.52% Upside in Biotech Sector - DirectorsTalk Interviews
Ascendis Pharma (ASND) Authorizes $400M Share Buyback - Yahoo Finance
Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs - Yahoo Finance
Ascendis Pharma (ASND) Stock Looks Near Fair Value On Infant Trial Data - simplywall.st
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost? - Yahoo Finance
Ascendis faces financial setback after patent dispute – Yet the CEO sees the outcome as a victory - medwatch.com
Novo Nordisk ends $285M TransCon partnership with Ascendis, which will now develop monthly obesity drug itself - Dealroom
Ascendis Pharma: Back To Full Independence (NASDAQ:ASND) - Seeking Alpha
Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says - finance.yahoo.com
H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end - Investing.com
Ascendis regains obesity rights as Novo exits monthly GLP-1 deal - thepharmaletter.com
Ascendis CEO after scrapped Novo partnership: Big mistake to be dependent on Big Pharma - medwatch.com
Ascendis Pharma (ASND) Reclaims Global TransCon Rights For Obesity And Heart Disease - simplywall.st
Why Is Ascendis Pharma Stock Trading Lower on Tuesday? - TradingView
Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send? - TradingKey
Ascendis Pharma Slides as Investors Weigh Novo Rights Reversion Despite Buyback - Quiver Quantitative
Ascendis Pharma Cut to Outperform From Strong Buy by Raymond James - Moomoo
Ascendis Pharma at Morgan Stanley conference: cash flow, growth and rights - Investing.com
Novo still seeks a long-acting treatment after scrapped deal with Ascendis - medwatch.com
Ascendis Pharma (NASDAQ: ASND) board okays discretionary $400M share buyback - Stock Titan
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis - Fierce Biotech
Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback - marketscreener.com
Novo Nordisk deal ends as Ascendis (NASDAQ: ASND) takes back obesity drug rights, with more programs shifting over - Stock Titan
Novo Nordisk, Ascendis Pharma End Metabolic, Cardiovascular Partnership - marketscreener.com
Ascendis Pharma authorizes $400 million share buyback program - Investing.com
Ascendis Pharma Authorizes Up to $400 Million Share Repurchase Program - Quiver Quantitative
Ascendis plans a once-monthly obesity drug after its Novo deal ends - Stock Titan
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today - benzinga.com
Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup - ChartMill
Consensus Analysis | Ascendis Pharma | 2026-09-14 - Biostock
Ascendis Pharma A/S (ASND) Stock Analysis: Is the 18.6% Upside a Green Light for Investors? - DirectorsTalk Interviews
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
Ascendis Pharma (ASND) ReACHin Data Keeps The Bull Case Alive As Valuation Questions Linger - simplywall.st
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data By Investing.com - Investing.com Nigeria
Ascendis Pharma (NASDAQ: ASND) Issues 29,380 Employee Warrants at $270.09 Exercise Price - Kalkine Media
Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock - Benzinga
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy - Investing.com
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data - investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com India
Ascendis Pharma SVP Mads Bodenhoff Exercises Warrants and Sells 3,000 Shares on September 8, 2026 - Kalkine Media
Ascendis Pharma A S (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ascendis Pharma A S 주식 (ASND) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO |
Sep 08 '26 |
Sale |
270.19 |
3,000 |
810,570 |
0 |
3.06%
2.55%
자본화:
|
볼륨(24시간):